Biphenyl

Biphenyl

SCHEMBL122229

O=P(Cl)(Cl)Cl.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
CYP1A2 P05177 1/20 0.50
ACP3 P15309 2/20 0.46
PTPN5 P54829 2/20 0.44
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
CYP3A4 P08684 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NOTUM Q6P988 1/20 0.43
MMP3 P08254 1/20 0.43
BCL2L1 Q07817 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
MMP8 P22894 1/20 0.41
MMP14 P50281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL1913481 0.88 ACP3 (0.54) ALDH1A1CYP1A2ACP3PTPN5MMP3
Biphenyl SCHEMBL11506188 0.88 ACP3 (0.54) ALDH1A1CYP1A2ACP3PTPN5MMP3
Biphenyl SCHEMBL17182196 0.88 ACP3 (0.54) ALDH1A1CYP1A2ACP3PTPN5MMP3
Biphenyl SCHEMBL1913599 0.83 ACP3 (0.50) ALDH1A1CYP1A2ACP3PTPN5MAPT
SCHEMBL14245147 0.81 ACP3 (0.47) ALDH1A1CYP1A2ACP3PTPN5MAPT
SCHEMBL824518 0.81 CYP1A2 (0.46) ALDH1A1CYP1A2ACP3PTPN5MAPT
Biphenyl SCHEMBL3763955 0.80 ALDH1A1 (0.60) ALDH1A1ACP3PTPN5MMP3BCL2L1
Biphenyl SCHEMBL342228 0.80 ALDH1A1 (0.60) ALDH1A1ACP3PTPN5MMP3BCL2L1
Biphenyl SCHEMBL263925 0.80 ALDH1A1 (0.60) ALDH1A1ACP3PTPN5MMP3BCL2L1
Biphenyl SCHEMBL3727875 0.80 ALDH1A1 (0.60) ALDH1A1ACP3PTPN5MMP3BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122060096-A Preparation and application of life metal inulin chelate 菌霖医药科技(宁波)有限公司 2026-05-19 CN claimed
CN-122011027-A Preparation and application of hydrogen peroxide fluorescent probe based on furonitrile-xanthene 湘潭大学 2026-05-12 CN claimed
US-20260109723-A1 PHOSPHORYLATED BIO-BASED FLAME RETARDANTS UT BATTELLE LLC (US) 2026-04-23 US claimed
CN-116120239-B Aromatic six-membered cycloimidazole derivative, and preparation method and application thereof 沈阳药科大学 2025-06-24 CN claimed
CN-120118522-A High-flame-retardance insulating liquid silicone rubber and preparation method and application thereof 宁波东致杰电力科技有限公司 2025-06-10 CN claimed
CN-120025376-A Sulfathiazole-based P/N/S-containing halogen-free flame retardant, and preparation method and application thereof 江南大学 2025-05-23 CN claimed
CN-120025359-A Phenylboronic acid-based P/N/B-containing halogen-free flame retardant, and preparation method and application thereof 江南大学 2025-05-23 CN claimed
CN-119930927-A Multifunctional high-molecular flame retardant and preparation method thereof 海南大学 2025-05-06 CN claimed
CN-119877281-A Halogen-free flame retardant spray for ethanol-soluble cotton fabric and preparation method thereof 海南大学 2025-04-25 CN claimed
CN-119331353-B Nanometer silicon dioxide synergistic flame-retardant polypropylene composite material and preparation method thereof 合肥科拜尔新材料股份有限公司 2025-04-15 CN claimed
CN-101039678-A Imidazo[1,5a]triazolo[1,5d]benzodiazepine derivatives for the treatment of cognitive disorders HOFFMANN LA ROCHE (CH) 2007-09-19 CN claimed
CN-1705639-A Synthesis of intermediates useful in the synthesis of tubulin inhibitors WYETH CORP (US) 2005-12-07 CN claimed
US-6875866-B2 Process for synthesis of D1 receptor antagonists SCHERING CORPORATION (US) 2005-04-05 US claimed
CN-1147502-C Method for large-scale production of Di (uridine 5'-tetraphosphate) and salts thereof ӡ��ҩƷ�ɷ����޹�˾ 2004-04-28 CN claimed
CN-1144811-C Dinucleotide crystals ɽ����ʽ���� 2004-04-07 CN claimed
US-20030199690-A1 Process for synthesis of D1 receptor antagonists SCHERING CORPORATION 2003-10-23 US claimed
CN-1359387-A Dinucleotide crystals YAMASA CORP (JP) 2002-07-17 CN claimed
CN-1265114-A Method for large-scale production of Di (uridine 5'-tetraphosphate) and salts thereof INSPIRE PHARMACEUTICALS INC (US) 2000-08-30 CN claimed
CN-1039023-A The HMG CoA reductase of 5-oxidation is torn preparation open MERCK & CO INC (US) 1990-01-24 CN claimed
US-4110441-A GAMMA-L-GLUTAMYL CHOLAMINE PHOSPHATE CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1978-08-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109723-A1 PHOSPHORYLATED BIO-BASED FLAME RETARDANTS DUSP4, DUSP23, FOS ALDH1A1 1769/4885CYP1A2 3006/4885ACP3 263/4885
US-20030199690-A1 Process for synthesis of D1 receptor antagonists OPRL1, AVPR1A, AVPR1B ALDH1A1 359/4885CYP1A2 636/4885ACP3 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.